Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash & Current Investments (2020 - 2025)

Insight Molecular Diagnostics' Cash & Current Investments history spans 6 years, with the latest figure at $19.4 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 471.44% year-over-year to $19.4 million; the TTM value through Sep 2025 reached $19.4 million, up 471.44%, while the annual FY2024 figure was $8.6 million, 8.44% down from the prior year.
  • Cash & Current Investments for Q3 2025 was $19.4 million at Insight Molecular Diagnostics, down from $24.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $47.6 million in Q2 2021 and bottomed at $400000.0 in Q3 2022.
  • The 5-year median for Cash & Current Investments is $14.4 million (2023), against an average of $18.2 million.
  • The largest annual shift saw Cash & Current Investments plummeted 99.1% in 2022 before it soared 773.21% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $33.9 million in 2021, then crashed by 39.66% to $20.4 million in 2022, then plummeted by 53.82% to $9.4 million in 2023, then decreased by 8.44% to $8.6 million in 2024, then skyrocketed by 124.98% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Cash & Current Investments are $19.4 million (Q3 2025), $24.3 million (Q2 2025), and $31.0 million (Q1 2025).